엘앤케이바이오메드
Public · 2 known investors
L&K Biomed develops spinal medical devices and related surgical products. The company focuses on research and development of orthopedic and spine healthcare technology.
Also known as (주)엘앤케이바이오메드 · L&K Biomed · L&K BIOMED · 엘앤케이바이오
Investors · 2
Company profile
researched Aug 2026L&K Biomed (㈜엘앤케이바이오메드) is a South Korean medical device manufacturer specializing in implants used to treat spinal disease. Founded in 2008, the company operates production systems covering cervical, thoracic and lumbar indications, and organizes its spine portfolio around expandable cages, cervical devices, thoracolumbar fixation, minimally invasive surgery (MIS) systems and sacroiliac (SI) joint fusion. A separate Pectus line addresses chest-wall deformity (pectus excavatum) implants, marketed as 'Pactus'/'CastleLoc-Pactus'.
Product families disclosed by the company include the LnK spinal fixation, cervical plate and interbody fusion cage systems, PathLoc series (PathLoc-C, PathLoc-L MIS, PathLoc-LC, PathLoc-SI, PathLoc-TM), CastleLoc series (CastleLoc-S, CastleLoc-P), OpenLoc-L, the ASK System, AccelFix fixation and AccelFix-MIS/XT/XTP, and the BluEX height-expandable cage series including BluEX-TM, BluEX-LT and the cervical BluEX-C. The company reports FDA clearances for these systems dating from 2010 onward, including what it describes as the world's first FDA authorization of a cervical minimally invasive surgery system in 2016 and Korea's first domestically developed expandable cage clearance in 2019.
The company runs an in-house corporate research institute (established 2009), a second research center in Gasan-dong, Seoul (2015), and a Yongin plant and R&D Center completed in 2013, with a second plant expansion in 2020. It is listed on the KOSDAQ market and publishes annual audit, business and settlement reports through its website."]
Business model
L&K Biomed designs, manufactures and sells spinal implants and associated surgical instrument systems, generating revenue from product sales in Korea and export markets through overseas subsidiaries and distributors, including dealer agreements in the United States.
Sales of spinal implants, fixation systems, expandable cages and pectus implants, plus supply of surgical instrument sets, to hospitals and distributors domestically and abroad; reported 2025 revenue of KRW 21.71 billion.
Traction
Reported quarterly and annual results include 2024 revenue of KRW 22.78 billion with net income of KRW 5.72 billion, and 2025 revenue of KRW 21.71 billion with a net loss of KRW 14.32 billion. Company IR releases cite full-year 2024 operating profit of KRW 3.1 billion (up 51%) and net income of KRW 10.2 billion, Q2 2025 revenue of KRW 11.3 billion with operating profit of KRW 1.7 billion, Q1 2026 revenue of KRW 9.5 billion (up 7% year on year) with a return to operating and net profit, and Q2 2026 revenue of KRW 11.7 billion. PathLoc-TM surpassed 2,500 US surgical cases in September 2024, 3,000 in January 2025 and 4,000 by July 2025, and the Pactus pectus implant is reported to have exceeded KRW 1 billion in monthly sales.
Latest developments
In 2025-2026 the company obtained US FDA clearance for the Pactus pectus implant (April 2025), BluEX-TM (July 2025), the cervical height-expandable BluEX-C (May 2026, with an additional size clearance in August 2026), and CastleLoc-P and AccelFix-MIS dual-thread systems (May 2026). It completed Thai product registration for Pactus, entered US Veterans Affairs hospitals, reported the first clinical use of BluEX-LT and the first, then four-level, cervical cases with BluEX-C, ran cadaver workshops with the Cleveland Clinic and other hospitals, secured land and buildings for a dedicated production base for global major customers (February 2026), and issued a KRW 32 billion convertible bond in January 2026.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
The company positions itself as a global spinal implant specialist and cites domestic firsts, including the first Korean-developed expandable cage approval and the first Korean spinal implant supplier to enter US Veterans Affairs hospitals. It reports premium pricing for BluEX-C in the US cervical/ACDF market and describes its expandable cage and pectus implant lines as its principal growth drivers.
Differentiation claims center on being first to obtain FDA authorization for a cervical minimally invasive surgery system (2016), the first domestically developed expandable cage approval in Korea (2019), a height-expandable cage line extended to the cervical spine (BluEX-C) with size ranges the company describes as unique, and a proprietary 'sandwich' technique for pectus excavatum implants.
Technology
The product base is metal and polymer spinal implant hardware: pedicle screw and rod fixation systems, anterior and posterior cervical plates and fixation, interbody fusion cages, MIS delivery systems, SI joint fusion devices, and height-expandable interbody cages (BluEX, AccelFix-XT/XTP, PathLoc-TM) that expand in situ, extended to the cervical spine with BluEX-C. The pectus line uses a proprietary implant and 'sandwich' surgical technique for chest-wall deformity correction. Development is carried out at the company's corporate research institute and R&D Center.
Go-to-market
The company sells through wholly owned or affiliated overseas entities (Aegis Spine in the US, Aegis Orthopaedics in Australia, and subsidiaries in Canada, Malaysia and India) and through distributor and dealer agreements, including a contract with a US mid-sized company for its height-expandable cage line. Clinical adoption is driven by cadaver workshops, live surgeries, symposia and participation in specialist congresses such as NASS, AANS, EuroSpine, SRS, JSPRS, CWIG and ICWSO, alongside coverage in US spine trade media, and it reports discussions with global major medical device firms on supply-chain expansion.
Spine and thoracic surgeons and hospitals, including large US hospital groups, academic medical centres such as the Cleveland Clinic and Chulalongkorn University Hospital in Thailand, children's hospitals treating chest-wall deformity, and US Veterans Affairs hospitals.
Geography
Headquarters and operations in South Korea (registered address in Giheung-gu, Yongin, Gyeonggi Province; originally founded in Mapo-gu, Seoul), with offices listed for Korea, Hong Kong, Vietnam, Thailand, Malaysia, India, Australia and the Americas. Regulatory approvals and market entries reported include the United States, Canada, Brazil, Portugal, the United Kingdom, Uzbekistan, Indonesia, Vietnam, Thailand and Japan.
History
The company was established in December 2008 in Mapo-gu, Seoul. It obtained KFDA manufacturing status in 2009 and set up a corporate research institute the same year, gained KGMP certification and its first US FDA clearance (LnK Basic Spinal Fixation System) in 2010, and received venture business certification in 2011. In 2012 it acquired 100% of US sales entity AEGIS SPINE, INC. and obtained further FDA clearances. It listed on the KONEX market in July 2013, the same year it completed the Yongin plant and R&D Center and received CE certification for the LnK Spinal Fixation System. Between 2015 and 2016 it added multiple FDA clearances, a second research center, trade awards (US$5 million tower in 2015, US$10 million tower in 2016), and listed on KOSDAQ on 30 November 2016. Overseas subsidiaries followed: L&K Biomed Canada (2017-01), L&K Biomed Malaysia (2017-05), L&K Biomed India (2018-03) and Aegis Orthopaedics Pty in Australia (2018-08); it also acquired 100% of H.J.C. Co. in 2017. In 2019 it received FDA clearance for its Lumbar Expandable Cage System and launched it in the US. In 2020 it expanded a second plant, obtained further FDA clearances, signed a strategic cooperation MOU with surgical robot company Curexo, registered expandable products with Beaumont Healthcare in Michigan, recruited spine specialist Professor Yoon Do-heum as technical advisor, and its affiliate Rootlock listed on KONEX.
Risks & controversies
The company reported a net loss of KRW 14.32 billion for fiscal 2025 after profit in 2024. It has relied repeatedly on convertible bond issuance, including a 10th CB decided in May 2024 and a KRW 32 billion CB in January 2026, and issued shareholder statements in December 2025 responding to media reports about its fundraising and in May 2026 about the status and timing of global contracts. US litigation involving the company was reported as concluded in July 2024. Employee review site Jobplanet shows an aggregate rating of 2.2 across roughly 149-150 reviews with a 23% recommendation rate.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
▸Research sources · 8
primary sources listed
- 엘앤케이바이오메드lnkbiomed.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does 엘앤케이바이오메드 do?
- L&K Biomed is a Korean maker of spinal implants and surgical systems, including height-expandable cages and pectus implants.
- Who are 엘앤케이바이오메드's investors?
- 엘앤케이바이오메드's investors include Hyundai Venture Investment Corporation, Laguna Investment.